Lawrence Steinman Selected Research

Paralysis (Palsy)

12/2017	Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
1/2017	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4.
12/2015	Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
11/2014	From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
2/2014	Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
6/2013	Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
4/2013	Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation.
8/2012	Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis.
7/2012	Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.
7/2011	IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lawrence Steinman Research Topics

Disease

104	Multiple Sclerosis 10/2022 - 01/2002
61	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2019 - 05/2002
35	Autoimmune Diseases (Autoimmune Disease) 11/2020 - 01/2002
27	Inflammation (Inflammations) 05/2020 - 04/2006
21	Neuroinflammatory Diseases 01/2018 - 06/2003
19	Paralysis (Palsy) 12/2017 - 11/2002
14	Neoplasms (Cancer) 10/2022 - 06/2002
14	Demyelinating Diseases (Demyelinating Disease) 01/2017 - 11/2002
12	Neuromyelitis Optica (Devic's Disease) 12/2019 - 10/2009
10	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2019 - 04/2002
9	Rheumatoid Arthritis 12/2019 - 03/2002
9	Relapsing-Remitting Multiple Sclerosis 12/2013 - 09/2002
8	Disease Progression 11/2019 - 09/2002
6	Encephalitis (Encephalitis, Rasmussen) 01/2019 - 01/2006
6	Narcolepsy 12/2016 - 01/2011
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2015 - 03/2002
6	Encephalomyelitis (Myeloencephalitis) 01/2015 - 09/2003
5	Infections 01/2021 - 02/2007
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 06/2003
5	Human Influenza (Influenza) 12/2016 - 05/2014
5	Brain Diseases (Brain Disorder) 12/2015 - 01/2007
4	COVID-19 12/2022 - 01/2020
4	Progressive Multifocal Leukoencephalopathy 01/2021 - 06/2005
4	Stroke (Strokes) 01/2019 - 08/2011
4	Alzheimer Disease (Alzheimer's Disease) 07/2014 - 06/2003
4	Arthritis (Polyarthritis) 01/2010 - 10/2006
3	Ischemia 01/2019 - 06/2011
3	Huntington Disease (Huntington's Disease) 01/2018 - 01/2002
3	Atherosclerosis 02/2016 - 12/2005
3	Hypersensitivity (Allergy) 12/2014 - 11/2003
3	Nervous System Diseases (Neurological Disorders) 05/2014 - 09/2011
3	Necrosis 12/2009 - 11/2002
3	Anaphylaxis (Anaphylactic Shock) 04/2009 - 02/2003
3	Experimental Arthritis 01/2008 - 10/2006

Drug/Important Bio-Agent (IBA)

30	AntigensIBA 01/2020 - 04/2002
23	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
21	Peptides (Polypeptides)IBA 01/2019 - 12/2002
20	AntibodiesIBA 10/2022 - 01/2006
20	CytokinesIBA 01/2019 - 05/2002
17	AutoantibodiesIBA 01/2020 - 01/2002
15	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2014 - 11/2002
14	AutoantigensIBA 12/2019 - 03/2002
13	VaccinesIBA 01/2020 - 04/2002
10	Biological ProductsIBA 01/2021 - 01/2002
10	Natalizumab (Tysabri)FDA Link 01/2021 - 06/2005
10	Pharmaceutical PreparationsIBA 05/2020 - 06/2005
10	Crystallins (Crystallin)IBA 01/2019 - 07/2007
10	Amyloid (Amyloid Fibrils)IBA 01/2018 - 08/2012
9	InterferonsIBA 01/2017 - 11/2002
8	DNA VaccinesIBA 05/2014 - 09/2003
7	EpitopesIBA 01/2020 - 10/2003
7	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 04/2002
6	ozanimodIBA 10/2022 - 01/2019
6	EnzymesIBA 01/2021 - 02/2006
6	Small Heat-Shock ProteinsIBA 01/2018 - 03/2012
6	Insulin (Novolin)FDA Link 01/2016 - 02/2003
6	Interleukin-6 (Interleukin 6)IBA 08/2014 - 05/2002
6	Atorvastatin (Lipitor)FDA Link 02/2014 - 11/2002
6	Interleukin-17 (Interleukin 17)IBA 11/2013 - 02/2007
5	Biomarkers (Surrogate Marker)IBA 11/2021 - 06/2006
5	LipidsIBA 04/2015 - 09/2005
5	Interferon-betaIBA 08/2013 - 09/2002
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013 - 11/2002
4	Monoclonal AntibodiesIBA 01/2021 - 06/2005
4	Polysaccharides (Glycans)IBA 01/2020 - 03/2009
4	Amino Acids FDA Link 12/2015 - 04/2013
4	LigandsIBA 07/2015 - 09/2005
4	Histamine (Histamine Dihydrochloride)FDA Link 12/2014 - 01/2006
4	Glatiramer Acetate (Copaxone)FDA Link 11/2014 - 09/2002
4	Transforming Growth Factor beta (TGF-beta)IBA 08/2010 - 08/2007
4	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 12/2009 - 10/2007
3	Amyloidogenic ProteinsIBA 01/2018 - 07/2014
3	Myelin ProteinsIBA 01/2018 - 10/2007
3	Immunoglobulin G (IgG)IBA 01/2018 - 04/2009
3	ProinsulinIBA 01/2018 - 06/2013
3	NucleoproteinsIBA 12/2016 - 07/2015
3	Orexin ReceptorsIBA 12/2016 - 07/2015
3	pandemrixIBA 12/2016 - 07/2015
3	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2016 - 11/2015
3	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2016 - 02/2003
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 04/2015 - 10/2007
3	Histamine Receptors (Histamine Receptor)IBA 12/2014 - 02/2003
3	Therapeutic UsesIBA 02/2014 - 08/2007
3	Tryptophan (L-Tryptophan)FDA Link 01/2014 - 11/2005
3	GpG-oligonucleotideIBA 03/2010 - 11/2003
3	CholesterolIBA 07/2008 - 05/2006
3	Oxidoreductases (Dehydrogenase)IBA 10/2007 - 12/2005
2	Sphingosine-1-Phosphate ReceptorsIBA 06/2021 - 11/2013
2	Alemtuzumab (Campath)FDA Link 11/2020 - 01/2017
2	Rituximab (Mabthera)FDA Link 11/2020 - 01/2013
2	Immunoglobulin M (IgM)IBA 01/2020 - 03/2009
2	CarbohydratesIBA 01/2020 - 03/2009
2	AngiotensinsIBA 01/2020 - 07/2009
2	Protein Glutamine gamma Glutamyltransferase 2IBA 12/2019 - 11/2015
2	GadoliniumIBA 11/2019 - 11/2019
2	Interferon beta-1a FDA Link 11/2019 - 11/2019
2	Retinaldehyde (Retinal)IBA 01/2019 - 01/2017

Therapy/Procedure

51	Therapeutics 12/2022 - 01/2002
7	Immunotherapy 10/2022 - 02/2003
3	Drug Therapy (Chemotherapy) 10/2022 - 09/2002